KRT7 and neoplasm: Some tumor sections were immunostained with ready-to-use primary antibodies against broad-spectrum cytokeratin (CK), vimentin, CD117, CK5/6, CK7, P40, P63, thyroid transcription factor-1 (TTF-1), smooth muscle actin, CD56, napsin A, synaptophysin, S-100, and Ki-67 (Maixin, Fuzhou, China).